Marinus Pharmaceuticals Inc - Company Profile
Powered by 
All the sales intelligence you need on Marinus Pharmaceuticals Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Marinus Pharmaceuticals Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Marinus Pharmaceuticals Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Marinus Pharmaceuticals Inc (Marinus Pharmaceuticals) is a biopharmaceutical company that carries out the business of development of innovative therapeutics for the treatment of seizure disorders, including rare genetic epilepsies and status epilepticus. The company's product include Ganaxolone, a novel gamma-aminobutyric acid ganaxolone receptor modulator type A (GABAA) receptor modulator is designed for the treatment of childhood disintegrative disorder (CDD). It markets its products under Ztalmy brand. It focusses in the areas of treatment including status epilepticus (SE), cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD), tuberous sclerosis complex (TSC). It serves healthcare providers, caregivers, healthcare professionals, and others. Marinus Pharmaceuticals is headquartered in Radnor, Pennsylvania, the US.
Headquarters
United States of America
Address
5 Radnor Corporate Center Suite 500, 100 Matsonford Rd, Pennsylvania, 19087
Website
marinuspharma.com
Telephone
1 484 8014670
No of Employees
165
Industry
Pharmaceuticals and Healthcare
Revenue (2023)
$31.0M
Marinus Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Product: | Ztalmy |
| Ganaxolone Receptor Modulator Type A (GABAA) |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Ownership Changes | In February, the company was acquired by Immedica Pharma AB, a global rare disease company. |
| 2022 | Contracts/Agreements | In November, the company entered into an agreement with Tenacia Biotechnology for the development of innovative treatments for central nervous system (CNS) disorders. |
| 2022 | Stake Sale | In October, the company sold a US$32.5 million revenue interest in ganaxolone to Sagard Healthcare Partners. |
Competitor Comparison
| Key Parameters | Marinus Pharmaceuticals Inc | Alexion Pharmaceuticals Inc | Alnylam Pharmaceuticals Inc | Galera Therapeutics Inc | Soleno Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Radnor | Boston | Cambridge | Malvern | Redwood City |
| State/Province | Pennsylvania | Massachusetts | Massachusetts | Pennsylvania | California |
| No. of Employees | 165 | 5,000 | 2,500 | 3 | 182 |
| Entity Type | Private | Private | Public | Public | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Steven E. Pfanstiel | Chief Financial Officer; Treasurer; Chief Operating Officer | Senior Management | 2021 | 51 |
| Sonya Weigle | Chief People Officer; Chief Investor Relations Officer | Senior Management | - | - |
| Joseph Hulihan, M.D. | Chief Medical Officer | Senior Management | 2019 | 68 |
| Charles Austin | Chief Scientific Officer | Senior Management | 2020 | 67 |
| Alex Aimetti, Ph.D. | Chief Scientific Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer